Neuroprotection Market, By Product Type, By Disease Indication, By Mechanism of Action, By End User, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

REPORT HIGHLIGHT

Neuroprotection Market size was valued at US$ 34,092.43 Million in 2024, expanding at a CAGR of 7.42% from 2025 to 2032.

The neuroprotection market refers to the industry focused on developing therapies and products aimed at protecting the nervous system, particularly the brain and spinal cord, from damage caused by diseases, injuries, or aging. This market addresses conditions such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, and traumatic brain injuries. Neuroprotective treatments can involve drug therapies, antioxidants, neurotrophic factors, and other interventions that help prevent or reduce neuronal damage.

The growth of this market is driven by the increasing prevalence of neurological disorders, advances in medical research, and the rising demand for effective treatments. Additionally, the aging global population further fuels the market as neurodegenerative diseases become more common. Companies are heavily investing in innovative solutions, leading to an expanding range of therapeutic options in neuroprotection.

Neuroprotection Market- Market Dynamics

Advancements in biomarker discovery for early-stage neurodegenerative disease diagnosis.

Advancements in biomarker discovery play a critical role in the early diagnosis of neurodegenerative diseases, significantly driving the neuroprotection market. Biomarkers help detect neurological disorders at their onset, enabling earlier and more effective intervention, which is crucial for improving patient outcomes. These discoveries facilitate personalized treatment approaches, as biomarkers can identify specific disease subtypes and predict progression. Enhanced diagnostic precision can reduce healthcare costs by ensuring timely therapies and better management.

Academic institutions and research organizations are leading the charge, with collaborations fostering breakthroughs. For instance, the National Institute on Aging (NIA) in the U.S. is actively funding biomarker research for Alzheimer's disease, which has led to the development of several promising diagnostic markers. According to the NIA, over $300 million is allocated annually toward Alzheimer's research, much of which focuses on biomarker advancements. These developments not only enhance diagnostic accuracy but also support the broader trend of precision medicine in neurodegenerative care.

Neuroprotection Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.42% over the forecast period (2025-2032)

Based on product type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Disease Indication segmentation, Alzheimer's disease was the leading Disease Indication in 2024

Based on Mechanism of Action segmentation, Antioxidants was the leading Mechanism of Action in 2024

Based on End-User segmentation, Hospitals was the leading End-User in 2024

On the basis of region, North America was the leading revenue generator in 2024

Neuroprotection Market- Segmentation Analysis:

The Global Neuroprotection Market is segmented on the basis of Product Type, Disease Indication, Mechanism of Action, End User, and Region.

The market is divided into two categories based on product type: Medication and Devices. In the neuroprotection market, medications are the most significant segment. They dominate the market due to their direct role in treating neurological diseases and conditions like Alzheimer's, Parkinson's, and multiple sclerosis. Medications, including neuroprotective drugs, are designed to slow disease progression, protect neurons from damage, and improve patients' quality of life. This segment benefits from ongoing research, clinical trials, and regulatory approvals, driving demand for novel pharmaceutical treatments. The market for neuroprotective medications is expected to continue growing as advancements in neuroscience lead to more effective therapies.

The market is divided into six categories based on Disease Indication: Parkinson's Disease, Alzheimer's Disease, Stroke, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Others. In the neuroprotection market, Alzheimer's disease is the most significant disease indication. It holds the largest share due to the high prevalence of the disease worldwide and the increasing aging population. Alzheimer's triggers widespread neurodegeneration, creating a substantial demand for neuroprotective therapies aimed at slowing its progression. Ongoing advancements in drug development and the increasing focus on finding effective treatments have propelled this segment forward. As the need for innovative treatments grows, Alzheimer's disease remains a focal point for researchers and pharmaceutical companies.

Neuroprotection Market- Geographical Insights

The North American neuroprotection market is experiencing significant growth, driven by an aging population, increasing prevalence of neurodegenerative diseases like Alzheimer's, Parkinson's, and multiple sclerosis, and advances in biotechnology and pharmaceuticals. The U.S. holds the largest share, owing to strong healthcare infrastructure, substantial research funding, and a high demand for therapeutic solutions. Canada is also contributing to the market with growing investments in neuroprotective research and development. Furthermore, there is a rising focus on early-stage interventions and preventative treatments, as well as emerging drug therapies. Government initiatives and collaborations between academic institutions and private sectors are enhancing innovation in neuroprotective agents. However, challenges such as high drug development costs and regulatory hurdles remain. Despite this, the market outlook remains optimistic, with key players in the industry exploring novel treatment strategies to address unmet medical needs.

The United States is the dominant country in the North American neuroprotection market, largely due to its advanced healthcare system, high level of research and development, and substantial government funding for medical innovation. The country is home to many leading biotech and pharmaceutical companies focused on neurodegenerative diseases, contributing to the rapid development and commercialization of neuroprotective therapies. Additionally, the large and aging population in the U.S. presents a growing demand for treatments, making it a key driver of market growth.

Neuroprotection Market- Competitive Landscape:

The competitive landscape of the neuroprotection market is characterized by intense rivalry among pharmaceutical companies, biotech firms, and research institutions, all vying to develop effective treatments for neurological disorders. Major players such as Biogen, Novartis, and Eli Lilly dominate with established portfolios in neurodegenerative diseases like Alzheimer's and Parkinson's. Companies are focusing on innovative drug discovery, targeting new mechanisms like neuroinflammation and neuroregeneration. The market also sees collaborations between large pharmaceutical firms and smaller biotech companies to leverage advanced technologies like gene therapy and stem cell research.

The increasing prevalence of neurodegenerative diseases and the need for improved treatments drive fierce competition for market share. Regulatory approval processes and the high cost of R&D add layers of complexity, leading to a few dominant players with significant resources and expertise. New entrants are constantly looking for niche areas and breakthrough therapies to differentiate themselves.

Recent Developments:

In November 2023, the US Food and Drug Administration (FDA) met with BrainStorm Cell Therapeutics to discuss NurOwn, a device with the potential to alleviate symptoms of ALS. The meeting discussed the overall protocol design of a potential confirmatory Phase III trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROPROTECTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Biogen Inc.
Eli Lilly and Co.
Novartis AG
Roche Holding AG
Merck & Co.
Pfizer Inc.
Amgen Inc.
AbbVie Inc.
Johnson & Johnson
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Lundbeck A/S
GlaxoSmithKline (GSK)
AstraZeneca plc
Eisai Co., Ltd.
Neurocrine Biosciences, Inc.
Axovant Gene Therapies

GLOBALNEUROPROTECTION MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Medication
Antioxidants
Anti-inflammatory drugs
Calcium channel blockers
Free radical scavengers
Devices

GLOBAL NEUROPROTECTION MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

Parkinson's Disease
Alzheimer's Disease
Stroke
Multiple Sclerosis
Amyotrophic Lateral Sclerosis (ALS)
Traumatic Brain Injury (TBI)
Others

GLOBAL NEUROPROTECTION MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

Antioxidants
Mitochondrial Protection
Inflammation Modulation
Calcium Regulation
Neurogenesis Stimulation
Gene Therapy-Based

GLOBAL NEUROPROTECTION MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Clinics
Research Institutes
Home Care Settings

GLOBAL NEUROPROTECTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4932

1. Neuroprotection Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Neuroprotection Market Snippet by Product Type
- 2.1.2. Neuroprotection Market Snippet by Disease Indication
- 2.1.3. Neuroprotection Market Snippet by Mechanism of Action
- 2.1.4. Neuroprotection Market Snippet by End User
- 2.1.5. Neuroprotection Market Snippet by Country
- 2.1.6. Neuroprotection Market Snippet by Region
2.2. Competitive Insights

3. Neuroprotection Key Market Trends

3.1. Neuroprotection Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Neuroprotection Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Neuroprotection Market Opportunities
3.4. Neuroprotection Market Future Trends

4. Neuroprotection Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Neuroprotection Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Neuroprotection Market Landscape

6.1. Neuroprotection Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Neuroprotection Market - By Product Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
- 7.1.2. Medication
  - 7.1.2.1. Antioxidants
  - 7.1.2.2. Anti-inflammatory drugs
  - 7.1.2.3. Calcium channel blockers
  - 7.1.2.4. Free radical scavengers
- 7.1.3. Devices

8. Neuroprotection Market - By Disease Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
- 8.1.2. Parkinson's Disease
- 8.1.3. Alzheimer's Disease
- 8.1.4. Stroke
- 8.1.5. Multiple Sclerosis
- 8.1.6. Amyotrophic Lateral Sclerosis (ALS)
- 8.1.7. Traumatic Brain Injury (TBI)
- 8.1.8. Others

9. Neuroprotection Market - By Mechanism of Action

9.1. Overview
- 9.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
- 9.1.2. Antioxidants
- 9.1.3. Mitochondrial Protection
- 9.1.4. Inflammation Modulation
- 9.1.5. Calcium Regulation
- 9.1.6. Neurogenesis Stimulation
- 9.1.7. Gene Therapy-Based

10. Neuroprotection Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Clinics
- 10.1.4. Research Institutes
- 10.1.5. Home Care Settings

11. Neuroprotection Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Neuroprotection Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Neuroprotection Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Neuroprotection Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Neuroprotection Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Neuroprotection Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Neuroprotection Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Biogen Inc.
- 12.2.2. Eli Lilly and Co.
- 12.2.3. Novartis AG
- 12.2.4. Roche Holding AG
- 12.2.5. Merck & Co.
- 12.2.6. Pfizer Inc.
- 12.2.7. Amgen Inc.
- 12.2.8. AbbVie Inc.
- 12.2.9. Johnson & Johnson
- 12.2.10. Sanofi S.A.
- 12.2.11. Teva Pharmaceutical Industries Ltd.
- 12.2.12. Takeda Pharmaceutical Company Limited
- 12.2.13. Lundbeck A/S
- 12.2.14. GlaxoSmithKline (GSK)
- 12.2.15. AstraZeneca plc
- 12.2.16. Eisai Co., Ltd.
- 12.2.17. Neurocrine Biosciences, Inc.
- 12.2.18. Axovant Gene Therapies

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us